GIM
MLTX icon

Glenmede Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Glenmede Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,635
Closed -$313K – 1541
2025
Q2 		$313K Buy
+6,635
New +$270K ﹤0.01% 1091

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Glenmede Investment Management's MLTX Position: Q3 2025 in Review

Glenmede Investment Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 6,635 shares — an estimated $313K sold.

Glenmede Investment Management first reported a position in MLTX in Q2 2025 and held it in 1 quarter. The position peaked at $313K in Q2 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Glenmede Investment Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 6,635 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $313K.
  • Glenmede Investment Management first reported a position in MoonLake Immunotherapeutics in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's MoonLake Immunotherapeutics position peaked at $313K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.